Top

Journal of Radiation Oncology

Published in:

01-12-2014 | Original Research

Long-term clinical experience with helical tomotherapy for head and neck cancer

Authors: Allen M. Chen, Megan E. Daly, Jing Cui, Julian Perks, James A. Purdy, Stanley Benedict

Published in: Journal of Radiation Oncology | Issue 4/2014

Abstract

Objective

The objective of this study is to review a long-term single-institutional experience with helical tomotherapy (HT) for the radiotherapeutic management of head and neck cancer.

Methods

From February 2006 to January 2013, a total of 301 consecutive patients with squamous cell carcinoma of the head and neck were treated with HT to a median dose of 66 Gy (range, 60 to 72 Gy). One hundred and seventy patients (56 %) underwent definitive HT and 131 patients (44 %) were treated post-operatively after surgery. There was no significant imbalance in patient or disease characteristics among patients treated with or without surgery (p > 0.05). Megavoltage computed tomography (MVCT) scans were obtained for patient alignment prior to each delivered fraction. Concurrent chemotherapy was administered to 133 patients (43 %).

Results

The 3-year estimates of overall survival, local-regional control, and disease-free survival were 76, 82, and 69 %, respectively. No difference existed with any of these endpoints among patients treated by definitive surgery versus radiation (p > 0.05). The incidence of grade 3+ acute toxicity was 30 %, with the most common related to skin erythema/desquamation, oral mucositis, esophagitis, dysguesia, and xerostomia. Post-HT esophageal stricture requiring dilatation was diagnosed in 12 %. Thirty (10 %) and 16 patients (5 %) were gastrostomy tube-dependent at 6 months and 1 year after HT, respectively.

Conclusion

HT achieves clinical outcomes consistent with other IMRT methods and is an effective means of treatment for head neck cancer either as primary or post-operative therapy.

Fiorino C, Dell’Oca I, Pierelli A, Broggi S, De Martin E, Di Muzio M et al (2006) Significant improvement in normal tissue sparing and target coverage for head and neck cancer by means of helical tomotherapy. Radiother Oncol 78:276–282PubMedCrossRef

Sheng K, Molloy JA, Read PW (2006) Intensity-modulated radiation therapy (IMRT) dosimetry of the head and neck: a comparison of treatment plans using linear accelerator-based IMRT and helical tomotherapy. Int J Radiat Oncol Biol Phys 65:917–923PubMedCrossRef

Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (2009) AJCC Cancer Staging Manual (ed 7). Springer, New York

Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:547–581CrossRef

Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31:1341–1346PubMedCrossRef

Chao KS, Ozyigit G, Tran BN, Cenzig M, Dempsey JF, Low DA (2003) Patterns of failure in patients receiving definitive and postoperative IMRT for head and neck cancer. Int J Radiat Oncol Biol Phys 55:312–321PubMedCrossRef

Eisbruch A, Marsh LH, Dawson LA, Bradford CR, Teknos TN, Chepeha TB et al (2004) Recurrences near base of skull after IMRT for head-and-neck cancer: implications for target delineation in high neck and for parotid gland sparing. Int J Radiat Oncol Biol Phys 59:28–42PubMedCrossRef

Schoenfeld GO, Amdur RJ, Morris CG, Li CJ, Hinerman RW, Mendenhall WM (2008) Patterns of failure and toxicity after intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys 71:377–385PubMedCrossRef

Lee N, Xia P, Fischbein NJ, Akazawa P, Akazawa C, Quivey JM (2003) Intensity-modulated radiation therapy for head-and-neck cancer: the UCSF experience focusing on target volume delineation. Int J Radiat Oncol Biol Phys 57:49–60PubMedCrossRef

10.

Yao M, Dornfeld KJ, Buatti JM, Skwarchuk M, Tan H, Nguyen T et al (2005) Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma—the University of Iowa experience. Int J Radiat Oncol Biol Phys 63:410–421PubMedCrossRef

11.

Daly ME, Lieskovsky Y, Pawlicki T, Yau J, Pinto H, Kaplan M et al (2007) Evaluation of patterns of failure and subjective salivary function in patients treated with intensity modulated radiotherapy for head and neck squamous cell carcinoma. Head Neck 29:211–220PubMedCrossRef

12.

Montejo ME, Shrieve DC, Bentz BG, Hunt JP, Buchman LO, Agarwal N et al (2010) IMRT with simultaneous integrated boost and concurrent chemotherapy for locoregionally advanced squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 81:e845–e852PubMedCrossRef

13.

Huang K, Xia P, Chuang C, Weinberg V, Glastonbury CM, Eisele DW et al (2008) Intensity-modulated chemoradiation for treatment of stage III and IV oropharyngeal carcinoma: the University of California-San Francisco experience. Cancer 113:497–507PubMedCrossRef

14.

Garden AS, Morrison WH, Wong PF, Tung SS, Rosenthal DI, Dong L et al (2007) Disease-control rates following intensity-modulated radiation therapy for small primary oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 67:438–444PubMedCentralPubMedCrossRef

15.

Gregoire V, Coche E, Cosnard G, Hamoir M, Reychler H (2000) Selection and delineation of lymph node target volume in head and neck conformal radiotherapy: proposal for standardizing terminology and procedure based on the surgical experience. Radiother Oncol 56:135–150PubMedCrossRef

16.

Breen SL, Publiocver J, De Silva S, Pond G, Brock K, O’Sullivan B et al (2007) Intraobserver and interobserver variability in GTV delineation on FDG-PET-CT images of head and neck cancers. Int J Radiat Oncol Biol Phys 68:763–770PubMedCrossRef

17.

Das I, Cheng CW, Chopra KL, Mitra RK, Srivastava SP, Glatstein E (2008) Intensity-modulated radiation therapy dose prescription, recording, and delivery: patterns of variability among institutions and treatment planning systems. J Natl Cancer Inst 100:300–307PubMedCrossRef

18.

Eisbruch A, Harris J, Garden AS, Chao CK, Straube W, Harari PM et al (2010) Multi-institutional trial of accelerated hypofractionated intensity-modulated radiation therapy for early-stage oropharyngeal cancer (RTOG 00-22). Int J Radiat Oncol Biol Phys 76:1333–1338PubMedCentralPubMedCrossRef

19.

Chen AM, Farwell DG, Luu Q, Donald PJ, Perks J, Purdy JA (2011) Evaluation of the planning target volume in the treatment of head and neck cancer with intensity-modulated radiotherapy: what is the appropriate expansion margin in the setting of daily image guidance? Int J Radiat Oncol Biol Phys 81(4):943–949PubMedCrossRef

20.

Feng FY, Kim HM, Lyden TH, Haxer MJ, Worden FP, Feng M et al (2007) Intensity-modulated radiotherapy of head and neck cancer aiming to reduce dysphagia: early dose-effect relationships for the swallowing structures. Int J Radiat Oncol Biol Phys 68:1289–1299PubMedCrossRef

Title: Long-term clinical experience with helical tomotherapy for head and neck cancer
Authors: Allen M. Chen
Megan E. Daly
Jing Cui
Julian Perks
James A. Purdy
Stanley Benedict
Publication date: 01-12-2014
Publisher: Springer Berlin Heidelberg
Published in: Journal of Radiation Oncology / Issue 4/2014
Print ISSN: 1948-7894
Electronic ISSN: 1948-7908
DOI: https://doi.org/10.1007/s13566-014-0157-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2014

A mechanical eyeball phantom for uveal melanoma radiosurgery by cyberknife

Adjuvant radiotherapy after prostatectomy: have randomized clinical trials had any impact?

The aftermath of a radiation accident

Adoption of Radiation Therapy Oncology Group consensus guidelines for post-prostatectomy radiation therapy in an academic tertiary care center

A phase II trial of balloon-catheter partial breast brachytherapy optimization in the treatment of stage 0, I, and IIA breast carcinoma

A phase II study of surgical excision, temozolomide, radiotherapy, and anti-EGFR radioimmunotherapy (EXTRA) as adjuvant therapy in high-grade gliomas

Keynote webinar | Spotlight on antibody–drug conjugates in cancer